3 Diagnostic Stocks With a Strong Future Roadmap: Dr. Lal PathLabs, Metropolis Healthcare and Vijaya Diagnostic Centre
- October 6, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Dr Lal PathLabs Rs 1,971.30, P/E 60.54. Metropolis Rs 553.60, P/E 56.76. Vijaya Diagnostic Rs 1,422.20, P/E 78.19. Closing prices of 5 Oct 2026.
Quick Answer
Diagnostic stocks with the clearest long-term roadmaps today include Dr. Lal PathLabs in pathology tests through a large lab and collection centre network, Metropolis Healthcare in pathology and specialised diagnostics with a hub-and-spoke network and Vijaya Diagnostic Centre in pathology and radiology centres under one roof. FY26 revenue growth was 12.1% at Dr Lal PathLabs, 24.1% at Metropolis and 19.3% at Vijaya Diagnostic. P/E stands at 60.54 for Dr Lal PathLabs (industry 64.07), 56.76 for Metropolis (industry 64.07) and 78.19 for Vijaya Diagnostic (industry 64.07). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Diagnostic stocks give investors exposure to the shift from treatment to testing in Indian healthcare. Results depend on test volumes, the number of collection centres and operating margin, which is why network reach and pricing matter as much as growth.
This list covers three diagnostic chain stocks: Dr. Lal PathLabs for pathology tests through a large lab and collection centre network, Metropolis Healthcare for pathology and specialised diagnostics with a hub-and-spoke network and Vijaya Diagnostic Centre for pathology and radiology centres under one roof. Every figure comes from the latest reported financials and the 5 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Diagnostic Stocks?
Diagnostic stocks are shares of companies that run pathology labs, radiology centres and collection networks. Results depend on test volumes, the mix of routine and specialised tests, B2B and B2C demand and operating margin, so network density and brand trust separate the stronger names.
Diagnostic Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three diagnostic stocks as of the 5 October 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Dr. Lal PathLabs | 1,971.30 | 33,078 | 60.54 | 64.07 | 20.13% | 0.08 |
| Metropolis Healthcare | 553.60 | 11,516 | 56.76 | 64.07 | 12.56% | 0.15 |
| Vijaya Diagnostic Centre | 1,422.20 | 14,657 | 78.19 | 64.07 | 18.07% | 0.44 |
Among diagnostic chain stocks, Dr Lal PathLabs and Metropolis trade below the industry P/E, while Vijaya Diagnostic trades at a premium to the industry multiple.
Why Do Diagnostic Stocks Have a Strong Roadmap in India?
Diagnostic stocks have a strong roadmap in India because awareness of preventive health is rising, more tests are prescribed and organised labs are taking share from small local ones. Three drivers stand out.
- Preventive health: Regular check-ups and wellness packages raise the number of tests per person.
- Organised share: Branded labs win share from small local labs on trust and quality.
- Network expansion: New collection centres and home collection widen reach in smaller cities.
Dr. Lal PathLabs: A Large Network and Preventive Health Anchor the Roadmap
Dr Lal PathLabs’ roadmap rests on a large lab and collection centre network, growth in preventive and wellness tests and wider reach in smaller cities.
Revenue grew from Rs 2,139.95 crore in FY22 to Rs 2,864.18 crore in FY26, a 33.8% rise, and FY26 revenue was 12.1% higher than FY25. FY26 net profit rose 3.6% to Rs 509.75 crore. Over four years, net profit rose from Rs 350.29 crore in FY22 to Rs 509.75 crore. In Q1 FY27, revenue grew 18.9% to Rs 829.60 crore, and net profit rose 27.2% to Rs 170.50 crore. Operating margin was 30.90% in FY26 and 35.03% in Q1 FY27 against 32.91% a year earlier.
Debt to equity is 0.08 and return on equity is 20.13%. FY26 operating cash flow was Rs 635.61 crore against capital expenditure of Rs 173.38 crore. Dr Lal PathLabs paid a dividend of Rs 20.5 per share for FY26, a yield of 1.04%. At a P/E of 60.54 against an industry P/E of 64.07, the stock trades below its industry multiple.
What to watch: FY26 net profit grew 3.6%, slower than the 35.9% rise in FY25, even as revenue rose 12.1%.
Metropolis Healthcare: Specialised Testing and Acquired Labs Drive the Pipeline
Metropolis’ roadmap rests on specialised and clinical testing, a hub-and-spoke network that widens reach and growth from acquired labs and home collection.
Revenue grew from Rs 1,245.96 crore in FY22 to Rs 1,671.43 crore in FY26, a 34.1% rise, and FY26 revenue was 24.1% higher than FY25. FY26 net profit rose 31.4% to Rs 191.18 crore. Over four years, net profit moved from Rs 214.69 crore in FY22 to Rs 191.18 crore. In Q1 FY27, revenue grew 15.7% to Rs 455.32 crore, and net profit rose 25.7% to Rs 56.88 crore. Operating margin was 25.63% in FY26 and 25.83% in Q1 FY27 against 25.20% a year earlier.
Debt to equity is 0.15 and return on equity is 12.56%. FY26 operating cash flow was Rs 350.70 crore against capital expenditure of Rs 51.18 crore. Metropolis paid a dividend of Rs 5 per share for FY26, a yield of 0.90%. At a P/E of 56.76 against an industry P/E of 64.07, the stock trades below its industry multiple.
What to watch: FY26 net profit of Rs 191.18 crore is still below the Rs 214.69 crore of FY22.
Vijaya Diagnostic Centre: Integrated Centres and New Cities Build the Next Leg
Vijaya Diagnostic’s roadmap rests on integrated pathology and radiology centres, new centres in southern and eastern cities and high operating margins.
Revenue grew from Rs 475.20 crore in FY22 to Rs 835.00 crore in FY26, a 75.7% rise, and FY26 revenue was 19.3% higher than FY25. FY26 net profit rose 20.3% to Rs 172.98 crore. Over four years, net profit rose from Rs 110.67 crore in FY22 to Rs 172.98 crore. In Q1 FY27, revenue grew 22.8% to Rs 239.51 crore, and net profit rose 37.6% to Rs 53.10 crore. Operating margin was 43.94% in FY26 and 46.35% in Q1 FY27 against 42.85% a year earlier.
Debt to equity is 0.44 and return on equity is 18.07%. FY26 operating cash flow was Rs 270.59 crore against capital expenditure of Rs 182.72 crore. Vijaya Diagnostic paid a dividend of Rs 2 per share for FY26, a yield of 0.14%. At a P/E of 78.19 against an industry P/E of 64.07, the stock trades above its industry multiple.
What to watch: The P/E of 78.19 is above the industry multiple of 64.07, and capital expenditure rose to Rs 182.72 crore in FY26. The P/E of 78.19 sits above the industry P/E of 64.07, so earnings delivery matters for the valuation.
Best Diagnostic Stocks in India: Dr Lal PathLabs vs Metropolis vs Vijaya Diagnostic on Key Financials
Among the best diagnostic stocks in India, Vijaya Diagnostic leads on FY26 operating margin and Q1 FY27 revenue growth; Dr Lal PathLabs leads on return on equity; Metropolis leads on the lowest P/E. The table puts the numbers side by side.
| Metric | Dr Lal PathLabs | Metropolis | Vijaya Diagnostic |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 2,864.18 | 1,671.43 | 835.00 |
| FY26 revenue growth | 12.1% | 24.1% | 19.3% |
| Revenue growth FY22 to FY26 | 33.8% | 34.1% | 75.7% |
| FY26 net profit (Rs Cr) | 509.75 | 191.18 | 172.98 |
| FY26 net profit growth | 3.6% | 31.4% | 20.3% |
| FY26 operating profit margin | 30.90% | 25.63% | 43.94% |
| Q1 FY27 revenue growth (YoY) | 18.9% | 15.7% | 22.8% |
| Q1 FY27 net profit growth (YoY) | 27.2% | 25.7% | 37.6% |
| Return on equity | 20.13% | 12.56% | 18.07% |
| P/E ratio | 60.54 | 56.76 | 78.19 |
| Debt to equity | 0.08 | 0.15 | 0.44 |
| Dividend yield | 1.04% | 0.90% | 0.14% |
| FY26 operating cash flow (Rs Cr) | 635.61 | 350.70 | 270.59 |
Diagnostic earnings follow test volumes and operating margin, so both growth and margin trends deserve a look.
How to Evaluate Pathology and Diagnostics Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen diagnostic stocks and shortlist pathology and diagnostics stocks to buy.
- Compare each stock’s P/E with its industry P/E, which is 64.07 for all three here.
- Track operating margin across several quarters, because input costs can move faster than prices.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Check the Univest Screener for live data on these diagnostic stocks
Risks to Consider Before Investing in Diagnostic Stocks
- Valuation: Vijaya Diagnostic trades at 78.19 times earnings against an industry multiple of 64.07, so a growth slowdown can weigh on the stock.
- Competition: Hospital chains, new labs and online players compete on price and convenience.
- Pricing pressure: Discounts from rivals can squeeze margins.
- Expansion cost: New centres need capital and take time to reach full volumes.
Download the Univest iOS App or Univest Android App to track Dr Lal PathLabs, Metropolis and Vijaya Diagnostic live.
Final Take: Which Stock Has the Strongest Roadmap?
These three pathology and diagnostics stocks cover pathology with a wide network, specialised testing with acquired labs, and integrated pathology and radiology centres. Vijaya Diagnostic leads on FY26 operating margin and Q1 FY27 revenue growth; Dr Lal PathLabs leads on return on equity; Metropolis leads on the lowest P/E.
Across diagnostic chain stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the pathology and diagnostics stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Diagnostic Stocks
Which are the best diagnostic stocks in India with a strong roadmap?
Ans. Dr. Lal PathLabs, Metropolis Healthcare and Vijaya Diagnostic Centre stand out for their roadmaps in pathology and radiology. FY26 revenue growth was 12.1% at Dr Lal PathLabs, 24.1% at Metropolis and 19.3% at Vijaya Diagnostic, and return on equity ranges from 12.56% to 20.13%.
Is Dr. Lal PathLabs a good stock to buy now?
Ans. Dr. Lal PathLabs has a debt to equity ratio of 0.08, a return on equity of 20.13% and a P/E of 60.54 against an industry P/E of 64.07. Competition and pricing pressure move results, and the stock trades at a premium valuation. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Dr Lal PathLabs, Metropolis and Vijaya Diagnostic?
Ans. The P/E ratio is 60.54 for Dr Lal PathLabs (industry 64.07), 56.76 for Metropolis (industry 64.07) and 78.19 for Vijaya Diagnostic (industry 64.07). Only Vijaya Diagnostic trades at or above the industry multiple.
Which of these diagnostic stocks has the highest return on equity?
Ans. Dr. Lal PathLabs has the highest return on equity at 20.13%, followed by Vijaya Diagnostic Centre at 18.07% and Metropolis Healthcare at 12.56%.
What are the risks of investing in diagnostic stocks?
Ans. The main risks are high valuations, price competition, hospital-run labs and the cost of opening new centres. Vijaya Diagnostic trades at 78.19 times earnings against an industry multiple of 64.07.
How did Dr Lal PathLabs, Metropolis and Vijaya Diagnostic perform in Q1 FY27?
Ans. Dr. Lal PathLabs reported revenue of Rs 829.60 crore, up 18.9% year on year, and net profit rose 27.2% to Rs 170.50 crore. Metropolis Healthcare reported revenue of Rs 455.32 crore, up 15.7% year on year, and net profit rose 25.7% to Rs 56.88 crore. Vijaya Diagnostic Centre reported revenue of Rs 239.51 crore, up 22.8% year on year, and net profit rose 37.6% to Rs 53.10 crore.
Do diagnostic stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 1.04% for Dr Lal PathLabs, 0.90% for Metropolis and 0.14% for Vijaya Diagnostic, based on dividends declared for FY26.
How can I invest in diagnostic stocks in India?
Ans. You can buy diagnostic stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.